Published in Nature on February 03, 2011
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol (2011) 4.23
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol (2012) 3.52
53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. Nature (2013) 2.64
RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J (2012) 2.34
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell (2011) 2.27
Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest (2012) 2.24
The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. Nat Struct Mol Biol (2011) 2.23
Chromatin remodeling at DNA double-strand breaks. Cell (2013) 2.18
Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks. Nat Struct Mol Biol (2014) 1.89
PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. Genes Dev (2012) 1.81
53BP1: pro choice in DNA repair. Trends Cell Biol (2013) 1.75
Chromatin and the genome integrity network. Nat Rev Genet (2013) 1.72
Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor. Proc Natl Acad Sci U S A (2014) 1.63
Histone H2A.Z controls a critical chromatin remodeling step required for DNA double-strand break repair. Mol Cell (2012) 1.63
SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep (2014) 1.57
Detection and repair of ionizing radiation-induced DNA double strand breaks: new developments in nonhomologous end joining. Int J Radiat Oncol Biol Phys (2013) 1.57
Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Res (2013) 1.55
53BP1, BRCA1, and the choice between recombination and end joining at DNA double-strand breaks. Mol Cell Biol (2014) 1.45
Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. Nat Rev Cancer (2012) 1.45
The proteasomal de-ubiquitinating enzyme POH1 promotes the double-strand DNA break response. EMBO J (2012) 1.44
Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov (2012) 1.43
SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife (2014) 1.33
DNA DSB repair pathway choice: an orchestrated handover mechanism. Br J Radiol (2014) 1.31
Double strand break repair functions of histone H2AX. Mutat Res (2013) 1.31
Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol Cell (2012) 1.29
An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res (2014) 1.29
BRCT domains: easy as one, two, three. Cell Cycle (2011) 1.25
SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem Sci (2013) 1.22
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest (2012) 1.21
Wolf-Hirschhorn syndrome candidate 1 is involved in the cellular response to DNA damage. Proc Natl Acad Sci U S A (2011) 1.18
USP51 deubiquitylates H2AK13,15ub and regulates DNA damage response. Genes Dev (2016) 1.12
Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases. EMBO J (2012) 1.10
Mammalian Ino80 mediates double-strand break repair through its role in DNA end strand resection. Mol Cell Biol (2011) 1.10
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia (2011) 1.08
Sex chromosome inactivation in germ cells: emerging roles of DNA damage response pathways. Cell Mol Life Sci (2012) 1.06
Dephosphorylation enables the recruitment of 53BP1 to double-strand DNA breaks. Mol Cell (2014) 1.05
Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Radiat Res (2013) 1.04
Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol (2013) 1.04
Reading, writing, and repair: the role of ubiquitin and the ubiquitin-like proteins in DNA damage signaling and repair. Front Genet (2013) 1.02
Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol (2012) 1.02
Impact of histone H4 lysine 20 methylation on 53BP1 responses to chromosomal double strand breaks. PLoS One (2012) 1.01
PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair. Proc Natl Acad Sci U S A (2014) 1.01
Co-operation of BRCA1 and POH1 relieves the barriers posed by 53BP1 and RAP80 to resection. Nucleic Acids Res (2013) 1.00
RNF168 ubiquitylates 53BP1 and controls its response to DNA double-strand breaks. Proc Natl Acad Sci U S A (2013) 1.00
Lamin B receptor recognizes specific modifications of histone H4 in heterochromatin formation. J Biol Chem (2012) 1.00
Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program (2011) 1.00
PCNA promotes processive DNA end resection by Exo1. Nucleic Acids Res (2013) 0.99
Initiation of DNA double strand break repair: signaling and single-stranded resection dictate the choice between homologous recombination, non-homologous end-joining and alternative end-joining. Am J Cancer Res (2012) 0.99
The role of epigenetics in the biology of multiple myeloma. Blood Cancer J (2014) 0.99
Epigenetics and B-cell lymphoma. Curr Opin Hematol (2011) 0.98
Polycomb repressive complex 2 contributes to DNA double-strand break repair. Cell Cycle (2013) 0.98
Overlapping functions between XLF repair protein and 53BP1 DNA damage response factor in end joining and lymphocyte development. Proc Natl Acad Sci U S A (2012) 0.97
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J (2012) 0.97
Deletions involving genes WHSC1 and LETM1 may be necessary, but are not sufficient to cause Wolf-Hirschhorn Syndrome. Eur J Hum Genet (2013) 0.97
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Chromatin modifications and the DNA damage response to ionizing radiation. Front Oncol (2013) 0.95
The histone variant macroH2A1.1 is recruited to DSBs through a mechanism involving PARP1. FEBS Lett (2012) 0.95
Histone acetyltransferase 1 promotes homologous recombination in DNA repair by facilitating histone turnover. J Biol Chem (2013) 0.95
Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma. Haematologica (2013) 0.95
Structural mechanism of the phosphorylation-dependent dimerization of the MDC1 forkhead-associated domain. Nucleic Acids Res (2012) 0.93
Chromatin dynamics in DNA double-strand break repair. Biochim Biophys Acta (2012) 0.93
Epigenetic regulation of genomic integrity. Chromosoma (2012) 0.93
The molecular basis of ATM-dependent dimerization of the Mdc1 DNA damage checkpoint mediator. Nucleic Acids Res (2012) 0.93
Chemical proteomics reveals a γH2AX-53BP1 interaction in the DNA damage response. Nat Chem Biol (2015) 0.92
Crosstalk between ubiquitin and other post-translational modifications on chromatin during double-strand break repair. Trends Cell Biol (2014) 0.91
FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer. PLoS One (2012) 0.90
Histone tails: Directing the chromatin response to DNA damage. FEBS Lett (2011) 0.90
WHSC1 links transcription elongation to HIRA-mediated histone H3.3 deposition. EMBO J (2013) 0.89
Histone demethylase KDM5B is a key regulator of genome stability. Proc Natl Acad Sci U S A (2014) 0.89
SIRT7 promotes genome integrity and modulates non-homologous end joining DNA repair. EMBO J (2016) 0.89
Nucleosome dynamics as modular systems that integrate DNA damage and repair. Cold Spring Harb Perspect Biol (2013) 0.89
Concerted activities of distinct H4K20 methyltransferases at DNA double-strand breaks regulate 53BP1 nucleation and NHEJ-directed repair. Cell Rep (2014) 0.89
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget (2013) 0.88
SPOC1 modulates DNA repair by regulating key determinants of chromatin compaction and DNA damage response. Nucleic Acids Res (2012) 0.88
ATM-Dependent Phosphorylation of All Three Members of the MRN Complex: From Sensor to Adaptor. Biomolecules (2015) 0.86
The histone methyltransferase MMSET regulates class switch recombination. J Immunol (2012) 0.86
DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle (2013) 0.86
Cross talk of tyrosine kinases with the DNA damage signaling pathways. Nucleic Acids Res (2015) 0.86
In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L. BMC Struct Biol (2014) 0.86
Metabolic modulation of chromatin: implications for DNA repair and genomic integrity. Front Genet (2013) 0.85
AIDing Chromatin and Transcription-Coupled Orchestration of Immunoglobulin Class-Switch Recombination. Front Immunol (2014) 0.85
Oligomerization of MDC1 protein is important for proper DNA damage response. J Biol Chem (2011) 0.84
V. Molecular classification and risk stratification of myeloma. Hematol Oncol (2013) 0.84
Histone H4 Lysine 20 (H4K20) Methylation, Expanding the Signaling Potential of the Proteome One Methyl Moiety at a Time. Mol Cell Proteomics (2015) 0.83
Molecular pathogenesis of multiple myeloma. Int J Clin Oncol (2015) 0.83
K48-linked ubiquitination and protein degradation regulate 53BP1 recruitment at DNA damage sites. Cell Res (2012) 0.83
MBTD1 is associated with Pr-Set7 to stabilize H4K20me1 in mouse oocyte meiotic maturation. Cell Cycle (2013) 0.83
KMT Set7/9 affects genotoxic stress response via the Mdm2 axis. Oncotarget (2015) 0.82
SET8 methyltransferase activity during the DNA double-strand break response is required for recruitment of 53BP1. EMBO Rep (2014) 0.82
Chromatin remodeling, DNA damage repair and aging. Curr Genomics (2012) 0.82
A dual role for the histone methyltransferase PR-SET7/SETD8 and histone H4 lysine 20 monomethylation in the local regulation of RNA polymerase II pausing. J Biol Chem (2014) 0.82
DNA double strand break repair pathway choice: a chromatin based decision? Nucleus (2015) 0.81
Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol (2016) 0.81
The histone H4 lysine 20 monomethyl mark, set by PR-Set7 and stabilized by L(3)mbt, is necessary for proper interphase chromatin organization. PLoS One (2012) 0.81
FANCD2 and REV1 cooperate in the protection of nascent DNA strands in response to replication stress. Nucleic Acids Res (2015) 0.80
The Tao of myeloma. Blood (2014) 0.80
RE-IIBP Methylates H3K79 and Induces MEIS1-mediated Apoptosis via H2BK120 Ubiquitination by RNF20. Sci Rep (2015) 0.80
MMSET: role and therapeutic opportunities in multiple myeloma. Biomed Res Int (2014) 0.80
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (2007) 20.11
RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell (2007) 9.25
RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell (2007) 8.71
A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev (2004) 8.66
Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol (2003) 8.55
MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell (2005) 8.39
Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell (2006) 8.12
Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science (2007) 7.61
The BRCT domain is a phospho-protein binding domain. Science (2003) 7.42
BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science (2003) 6.88
MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature (2003) 6.81
BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell (2001) 6.75
MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell (2006) 6.09
PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell (2002) 5.59
53BP1, a mediator of the DNA damage checkpoint. Science (2002) 5.00
Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell (2004) 4.99
DBC1 is a negative regulator of SIRT1. Nature (2008) 4.66
Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol (2002) 4.12
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood (1998) 3.69
Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1/NFBD1. J Cell Biol (2005) 3.69
A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse. Genes Dev (2008) 3.16
WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet (1998) 2.77
A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature (2009) 2.74
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
Histone modification-dependent and -independent pathways for recruitment of checkpoint protein Crb2 to double-strand breaks. Genes Dev (2006) 2.27
CtIP links DNA double-strand break sensing to resection. Mol Cell (2009) 2.11
Structure of the BRCT repeat domain of MDC1 and its specificity for the free COOH-terminal end of the gamma-H2AX histone tail. J Biol Chem (2005) 2.10
Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol (2008) 1.96
53BP1: function and mechanisms of focal recruitment. Biochem Soc Trans (2009) 1.90
The etiology of Wolf-Hirschhorn syndrome. Trends Genet (2005) 1.85
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer (2002) 5.30
DBC1 is a negative regulator of SIRT1. Nature (2008) 4.66
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell (2009) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell (2006) 3.53
CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science (2006) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 3.17
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Histone H3-K56 acetylation is important for genomic stability in mammals. Cell Cycle (2009) 2.77
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res (2008) 2.58
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell (2007) 2.56
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest (2012) 2.24
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood (2012) 2.07
Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr (2008) 2.01
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood (2010) 1.96
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood (2012) 1.88
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood (2005) 1.87
Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res (2010) 1.87
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood (2005) 1.81
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol (2010) 1.77
Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet (2006) 1.76
Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One (2009) 1.75
Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem (2006) 1.74
A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol (2009) 1.73
Human aromatase: gene resequencing and functional genomics. Cancer Res (2005) 1.71
DNA methylation contributes to natural human variation. Genome Res (2013) 1.66
The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell (2009) 1.64
MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks. Proc Natl Acad Sci U S A (2008) 1.63
Pharmacogenomics: bench to bedside. Nat Rev Drug Discov (2004) 1.63
Approach to the treatment of multiple myeloma: a clash of philosophies. Blood (2011) 1.57
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res (2009) 1.57
Prognostic factors in multiple myeloma: it's in the genes. Clin Cancer Res (2003) 1.55
MDC1 directs chromosome-wide silencing of the sex chromosomes in male germ cells. Genes Dev (2011) 1.52
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood (2004) 1.49
Sumoylation of MDC1 is important for proper DNA damage response. EMBO J (2012) 1.44
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood (2009) 1.44
Distinct versus overlapping functions of MDC1 and 53BP1 in DNA damage response and tumorigenesis. J Cell Biol (2008) 1.38
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc (2010) 1.34
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Topoisomerase IIalpha controls the decatenation checkpoint. Nat Cell Biol (2008) 1.32
Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res (2011) 1.32
IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther (2009) 1.28
Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J Immunol (2002) 1.27
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc Natl Acad Sci U S A (2010) 1.25
Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics (2005) 1.23
Loss of ATM kinase activity leads to embryonic lethality in mice. J Cell Biol (2012) 1.23
Regulation of SIRT1 activity by genotoxic stress. Genes Dev (2012) 1.22
Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest (2008) 1.22
Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase. J Biol Chem (2012) 1.19
Protein phosphatase 2A antagonizes ATM and ATR in a Cdk2- and Cdc7-independent DNA damage checkpoint. Mol Cell Biol (2006) 1.15
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res (2012) 1.13
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics (2011) 1.12
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov (2013) 1.12
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol (2011) 1.11
Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One (2011) 1.10
Smoldering multiple myeloma requiring treatment: time for a new definition? Blood (2013) 1.09
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood (2012) 1.09